134 related articles for article (PubMed ID: 35887930)
21. The Quality and Reliability of Information in the Summaries of Product Characteristics.
Drelich E; Religioni U; Chung K; Kaźmierczak J; Blicharska E; Neumann-Podczaska A; Krysiński J; Merks P
Int J Environ Res Public Health; 2022 Feb; 19(4):. PubMed ID: 35206371
[TBL] [Abstract][Full Text] [Related]
22. Contraindication labelling changes in the United States and Germany.
Garbe E; Andersohn F
Eur J Clin Pharmacol; 2007 Jan; 63(1):87-93. PubMed ID: 17124576
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
[TBL] [Abstract][Full Text] [Related]
24. The effect of framing and communicating COVID-19 vaccine side-effect risks on vaccine intentions for adults in the UK and the USA: A structured summary of a study protocol for a randomized controlled trial.
Sudharsanan N; Favaretti C; Hachaturyan V; Bärnighausen T; Vandormael A
Trials; 2021 Sep; 22(1):592. PubMed ID: 34488843
[TBL] [Abstract][Full Text] [Related]
25. An Adverse Drug Reaction Database for Clinical Use - Potential of and Difficulties with the Summary of Product Characteristics.
Eiermann B; Rodrigues D; Cohen P; Gustafsson LL
Stud Health Technol Inform; 2022 May; 294():450-454. PubMed ID: 35612120
[TBL] [Abstract][Full Text] [Related]
26. Analysis of Immunogenicity Data in the Product Information of Biological Drugs: A Need to Report Immunogenicity Data Systematically.
Borrega R; Cruz JP; Taylor P; Goncalves J
BioDrugs; 2019 Dec; 33(6):683-691. PubMed ID: 31595484
[TBL] [Abstract][Full Text] [Related]
27. Arrhythmias related to antipsychotics and antidepressants: an analysis of the summaries of product characteristics of original products approved in Germany.
Elsayed M; Abdel-Kahaar E; Gahr M; Connemann BJ; Denkinger M; Schönfeldt-Lecuona C
Eur J Clin Pharmacol; 2021 May; 77(5):767-775. PubMed ID: 33230596
[TBL] [Abstract][Full Text] [Related]
28. Results on patient-reported outcomes are underreported in summaries of product characteristics for new drugs.
Haag S; Junge L; Lotz F; McGauran N; Paulides M; Potthast R; Kaiser T
J Patient Rep Outcomes; 2021 Dec; 5(1):127. PubMed ID: 34874524
[TBL] [Abstract][Full Text] [Related]
29. Pharmacogenomic biomarker information differences between drug labels in the United States and Hungary: implementation from medical practitioner view.
Varnai R; Szabo I; Tarlos G; Szentpeteri LJ; Sik A; Balogh S; Sipeky C
Pharmacogenomics J; 2020 Jun; 20(3):380-387. PubMed ID: 31787752
[TBL] [Abstract][Full Text] [Related]
30. ADR databases for on-site clinical use: Potentials of summary of products characteristics.
Eiermann B; Rodriguez D; Cohen P; Gustafsson LL
Basic Clin Pharmacol Toxicol; 2021 Apr; 128(4):557-567. PubMed ID: 33523597
[TBL] [Abstract][Full Text] [Related]
31. "Legal highs" on the net-Evaluation of UK-based Websites, products and product information.
Schmidt MM; Sharma A; Schifano F; Feinmann C
Forensic Sci Int; 2011 Mar; 206(1-3):92-7. PubMed ID: 20650576
[TBL] [Abstract][Full Text] [Related]
32. The role of contraindications in prescribing anticoagulants to patients with atrial fibrillation: a cross-sectional analysis of primary care data in the UK.
Adderley N; Ryan R; Marshall T
Br J Gen Pract; 2017 Sep; 67(662):e588-e597. PubMed ID: 28630059
[TBL] [Abstract][Full Text] [Related]
33. The quality of information on monitoring for haematological adverse drug reactions.
Ferner RE; Coleman J; Pirmohamed M; Constable SA; Rouse A
Br J Clin Pharmacol; 2005 Oct; 60(4):448-51. PubMed ID: 16187979
[TBL] [Abstract][Full Text] [Related]
34. [Arterial Hyper- and Hypotension associated with psychiatric medications: a risk assessment based on the summaries of product characteristics (SmPCs)].
Freudenmann RW; Freudenmann N; Zurowski B; Schönfeldt-Lecuona C; Maier L; Schmieder RE; Lange-Asschenfeldt C; Gahr M
Dtsch Med Wochenschr; 2017 Aug; 142(16):e100-e107. PubMed ID: 28645134
[No Abstract] [Full Text] [Related]
35. How important is the role of the physician in the correct use of a drug? An observational cohort study in general practice.
Bradbury F
Int J Clin Pract Suppl; 2004 Oct; (144):27-32. PubMed ID: 16035400
[TBL] [Abstract][Full Text] [Related]
36. A comparative analysis of drug safety withdrawals in the UK and the US (1971-1992): implications for current regulatory thinking and policy.
Abraham J; Davis C
Soc Sci Med; 2005 Sep; 61(5):881-92. PubMed ID: 15955393
[TBL] [Abstract][Full Text] [Related]
37. Speaking the same language? International variations in the safety information accompanying top-selling prescription drugs.
Kesselheim AS; Franklin JM; Avorn J; Duke JD
BMJ Qual Saf; 2013 Sep; 22(9):727-34. PubMed ID: 23620531
[TBL] [Abstract][Full Text] [Related]
38. Elements of Regulatory Dissonance: Examining FDA and EMA Product Labeling of New Vaccines (2006-2018).
Seo Y; Pacifici E
Vaccine; 2020 Nov; 38(47):7485-7489. PubMed ID: 33059971
[TBL] [Abstract][Full Text] [Related]
39. Comparing cytochrome P450 pharmacogenetic information available on United States drug labels and European Union Summaries of Product Characteristics.
Reis-Pardal J; Rodrigues A; Rodrigues E; Fernandez-Llimos F
Pharmacogenomics J; 2017 Dec; 17(6):488-493. PubMed ID: 27241061
[TBL] [Abstract][Full Text] [Related]
40. Comorbidities, Age, and Polypharmacy Limit the Use by US Older Adults with Nocturia of the Only FDA-approved Drugs for the Symptom.
Suvada K; Plantinga L; Vaughan CP; Markland AD; Mirk A; Burgio KL; Erni SM; Ali MK; Okosun I; Young H; Goode PS; Johnson TM
Clin Ther; 2020 Dec; 42(12):e259-e274. PubMed ID: 33257091
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
